Alteration of tumor microenvironment for improved delivery and intratumor distribution of nanocarriers

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 5, 2013, Pages 692-697

  Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Anticancer therapy; Enhanced permeability and retention effect; Nanocarrier; Tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DECORIN; DIPHTHERIA TOXIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HYALURONIC ACID; LIPOSOME; NANOCARRIER; NANOPARTICLE; NITRIC OXIDE; PACLITAXEL; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CELL DENSITY; CELL PROLIFERATION; DIFFUSION; DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; EXTRAVASATION; HUMAN; NONHUMAN; REVIEW; SOLID TUMOR; TISSUE DISTRIBUTION; TUMOR BLOOD FLOW; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; NANOPARTICLES; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84876930668     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00121     Document Type: Review

References (67)

1. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today, 11, 812-818 (2006).
2. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res., 31, 288-305 (1986).
3. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A., 95, 4607-4612 (1998).
4. Yuan F, Leunig M, Berk DA, Jain RK. Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. Microvasc. Res., 45, 269-289 (1993).
5. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 46, 6387-6392 (1986).
6. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev., 65, 71-79 (2013).
7. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J. Control. Release, 164, 138-144 (2012).
8. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature, 427, 695 (2004).
9. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl. Acad. Sci. U.S.A., 97, 14608-14613 (2000).
10. di Tomaso E, Capen D, Haskell A, Hart J, Logie JJ, Jain RK, McDonald DM, Jones R, Munn LL. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res., 65, 5740-5749 (2005).
11. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat. Med., 9, 713-725 (2003).
12. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell, 6, 553-563 (2004).
13. Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP, Yuan F, Jain RK. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res., 59, 4129-4135 (1999).
14. Graff BA, Bjornaes I, Rofstad EK. Macromolecule uptake in human melanoma xenografts. relationships to blood supply, vascular density, microvessel permeability and extracellular volume fraction. Eur. J. Cancer, 36, 1433-1440 (2000).
15. Levick JR. Flow through interstitium and other fibrous matrices. Q. J. Exp. Physiol., 72, 409-437 (1987).
16. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E, Brown EB, Izumi Y, Campbell RB, Berk DA, Jain RK. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl. Acad. Sci. U.S.A., 98, 4628-4633 (2001).
17. 2 in solid tumors. Ann. Biomed. Eng., 28, 543-555 (2000).
18. Ohtani H. Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions. Pathol. Int., 48, 1-9 (1998).
19. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson J. Extracellular matrix of animals. Molecular Biology of the Cell. (3rd ed.) Garland Publishing, New York, pp. 971-995 (1994)
20. Gribbon PM, Maroudas A, Parker KH, Winlove CP. Water and solute transport in the extracellular matrix: physical principles and macromolecular determinants. Connective Tissue Biology. (Reed RK, Rubin K ed.) Portland Press, London, pp. 95-124 (1998)
21. Comper WD, Laurent TC. Physiological function of connective tissue polysaccharides. Physiol. Rev., 58, 255-315 (1978).
22. Alexandrakis G, Brown EB, Tong RT, McKee TD, Campbell RB, Boucher Y, Jain RK. Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors. Nat. Med., 10, 203-207 (2004).
23. Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, Scadden DT, Torchilin VP, Bawendi MG, Fukumura D, Jain RK. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med., 11, 678-682 (2005).
24. Arbiser JL, Raab G, Rohan RM, Paul S, Hirschi K, Flynn E, Price ER, Fisher DE, Cohen C, Klagsbrun M. Isolation of mouse stromal cells associated with a human tumor using differential diphtheria toxin sensitivity. Am. J. Pathol., 155, 723-729 (1999).
25. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res., 59, 3776-3782 (1999).
26. Suzuki M, Hori K, Abe I, Saito S, Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst., 67, 663-669 (1981).
27. Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet., 42, 1089-1105 (2003).
28. Hori K, Saito S, Takahashi H, Sato H, Maeda H, Sato Y. Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn. J. Cancer Res., 91, 261-269 (2000).
29. Li CJ, Miyamoto Y, Kojima Y, Maeda H. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer, 67, 975-980 (1993).
30. Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest, 128 (Suppl.), 585S-590S (2005).
31. Dickson K, Philip A, Warshawsky H, O'Connor-McCourt M, Bergeron JJ. Specific binding of endocrine transforming growth factor-beta 1 to vascular endothelium. J. Clin. Invest., 95, 2539-2554 (1995).
32. Larsson J, Goumans MJ, Sjöstrand LJ, van Rooijen MA, Ward D, Levéen P, Xu X, ten Dijke P, Mummery CL, Karlsson S. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J., 20, 1663-1673 (2001).
33. Oshima M, Oshima H, Taketo MM. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev. Biol., 179, 297-302 (1996).
34. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst., 98, 335-344 (2006).
35. Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, Miyazono K, Miyazawa K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J. Cell Sci., 118, 3759-3768 (2005).
36. Watanabe N, Tsuji N, Tsuji Y, Sasaki H, Okamoto T, Akiyama S, Kobayashi D, Sato T, Yamauchi N, Niitsu Y. Endogenous tumor necrosis factor inhibits the cytotoxicity of exogenous tumor necrosis factor and adriamycin in pancreatic carcinoma cells. Pancreas, 13, 395-400 (1996).
37. McIntosh JK, Mulé JJ, Travis WD, Rosenberg SA. Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice. Cancer Res., 50, 2463-2469 (1990).
38. Seynhaeve AL, Hoving S, Schipper D, Vermeulen CE, de Wiel-Ambagtsheer G, van Tiel ST, Eggermont AM, Ten Hagen TL. Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res., 67, 9455-9462 (2007).
39. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology, 69 (Suppl. 3), 4-10 (2005).
40. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med., 9, 669-676 (2003).
41. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS, 79, 233-269 (1997).
42. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev., 18, 4-25 (1997).
43. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 146, 1029-1039 (1995).
44. Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med., 196, 1497-1506 (2002).
45. Pal S, Iruela-Arispe ML, Harvey VS, Zeng H, Nagy JA, Dvorak HF, Mukhopadhyay D. Retinoic acid selectively inhibits the vascular permeabilizing effect of VPF/VEGF, an early step in the angiogenic cascade. Microvasc. Res., 60, 112-120 (2000).
46. Doi K, Akaike T, Horie H, Noguchi Y, Fujii S, Beppu T, Ogawa M, Maeda H. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer, 77 (Suppl.), 1598-1604 (1996).
47. Maeda H, Akaike T, Wu J, Noguchi Y, Sakata Y. Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology, 33, 222-230 (1996).
48. Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res., 58, 159-165 (1998).
49. Tanaka S, Akaike T, Wu J, Fang J, Sawa T, Ogawa M, Beppu T, Maeda H. Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium. J. Drug Target., 11, 45-52 (2003).
50. Netti PA, Hamberg LM, Babich JW, Kierstead D, Graham W, Hunter GJ, Wolf GL, Fischman A, Boucher Y, Jain RK. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. U.S.A., 96, 3137-3142 (1999).
51. Berk DA, Yuan F, Leunig M, Jain RK. Fluorescence photobleaching with spatial Fourier analysis: measurement of diffusion in light-scattering media. Biophys. J., 65, 2428-2436 (1993).
52. Brown EB, Wu ES, Zipfel W, Webb WW. Measurement of molecular diffusion in solution by multiphoton fluorescence photobleaching recovery. Biophys. J., 77, 2837-2849 (1999).
53. Köninger J, Giese NA, di Mola FF, Berberat P, Giese T, Esposito I, Bachem MG, Büchler MW, Friess H. Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action. Clin. Cancer Res., 10, 4776-4783 (2004).
54. Scott JE, Dyne KM, Thomlinson AM, Ritchie M, Bateman J, Cetta G, Valli M. Human cells unable to express decoron produced disorganized extracellular matrix lacking "shape modules" (interfibrillar proteoglycan bridges). Exp. Cell Res., 243, 59-66 (1998).
55. Beckenlehner K, Bannke S, Spruss T, Bernhardt G, Schönenberg H, Schiess W. Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo. J. Cancer Res. Clin. Oncol., 118, 591-596 (1992).
56. Smith KJ, Skelton HG, Turiansky G, Wagner KF, Themilitarymedicalconsortiumf, Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma. J. Am. Acad. Dermatol., 36, 239-242 (1997).
57. Eikenes L, Tari M, Tufto I, Bruland OS, de Lange Davies C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br. J. Cancer, 93, 81-88 (2005).
58. Magzoub M, Jin S, Verkman AS. Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin. FASEB J., 22, 276-284 (2008).
59. Nagano S, Perentes JY, Jain RK, Boucher Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res., 68, 3795-3802 (2008).
60. Lu D, Wientjes MG, Lu Z, Au JL. Tumor priming enhances delivery and efficacy of nanomedicines. J. Pharmacol. Exp. Ther., 322, 80-88 (2007).
61. Ishida T, Shiraga E, Kiwada H. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model. J. Control. Release, 134, 194-200 (2009).
62. Shiraga E, Barichello JM, Ishida T, Kiwada H. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model. Int. J. Pharm., 353, 65-73 (2008).
63. Doi Y, Okada T, Matsumoto H, Ichihara M, Ishida T, Kiwada H. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model. Cancer Sci., 101, 2470-2475 (2010).
64. Koga M, Anegawa E, Yoh J, Tsuyama H, Sakaino H, Iwamoto O, Koga C, Kusukawa J. Clinical relevance of thymidylate synthase (TS) activity for S-1-based chemotherapy in squamous cell carcinoma of the oral cavity. Br. J. Oral Maxillofac. Surg., 48, 88-93 (2010).
65. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res., 53, 4004-4009 (1993).
66. Uchida K, Hayashi K, Kuramochi H, Nakajima G, Inoue Y, Yamamoto M. Combination therapy of S-1 and CDDP for patients with colorectal cancer. J. Cancer Res. Clin. Oncol., 133, 841-846 (2007).
67. Nakamura K, Abu Lila AS, Matsunaga M, Doi Y, Ishida T, Kiwada H. A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol. Ther., 19, 2040-2047 (2011).